openPR Logo
Press release

Global Immune Check Point Inhibitors Clinical Pipeline Has 79 Drugs In Pipeline

07-08-2017 01:55 PM CET | Health & Medicine

Press release from: Kuick Resarch

Global Immune Check Point Inhibitors Clinical Pipeline Has 79

Global Immune Check Point Inhibitors Market and Clinical Pipeline Insight 2022” report highlights:

* Introduction and Mechanism of Action of Immune Checkpoint Inhibitors

* CTLA 4, PD-1 and PD-L1 Inhibition Approved Drugs to Target Immune Checkpoints

* Biomarkers Associated with Immune Checkpoint Inhibitors

* Combination Approaches with Immune Checkpoint Inhibitors

* Global Immune Checkpoint Inhibitors Clinical Pipeline

* Future Potential of Immune Checkpoint Inhibitors

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Download Report: https://www.kuickresearch.com/report-global-immune-check-point-inhibitors-market-and-clinical-pipeline-insight-2022.php

Report Table of Contents

Immune Checkpoint Inhibitors- Introduction to Next Generation Cancer Immunotherapy
1.1 Overview
1.2 History- From Tragedy to Breakthrough

Major Immune Checkpoints Proteins
2.1 Role of Cytotoxic T lymphocyte Antigen-4 (CTLA-4) in Cancer Development
2.2 Role of Programed Cell Death Protein 1 (PD1) in Cancer Development

Mechanism of Action of Immune Checkpoint Inhibitors
3.1 Cytotoxic T lymphocyte Antigen-4 (CTLA-4)
3.1 Programed Death Protein-1 (PD1)

CTLA 4 Inhibition Approved Drugs to Target Immune Checkpoints
4.1 Ipilimumab (Yervoy: Melanoma)

PD-1 and PD-L1 Inhibition Approved Drugs to Target Immune Checkpoints
5.1 Nivolumab (Opdivo: Hodgkin Lymphoma, Urothelial Carcinoma and NSCLC)
5.2 Pembrolizumab (Keytruda: Melanoma and NSCLC)
5.3 Atezolizumab (Tecentriq: Solid Tumors)

Biomarkers Associated with Immune Checkpoint Inhibitors
6.1 Predictive Biomarkers to Anti-CTLA 4
6.2 Predictive Biomarker to Anti-PD 1

Combination Approaches with Immune Checkpoint Inhibitors
7.1 Combination with Conventional Methods
7.1.1 Chemotherapy
7.1.2 Targeted Therapies
7.1.3 Radiotherapy
7.2 Combination with Cancer Vaccines
7.2.1 Peptide Vaccines
7.2.2 Cellular Vaccines
7.2.3 Oncolytic Viruses

Global Immune Checkpoint Inhibitors Market

Global Immune Checkpoint Inhibitors Clinical Pipeline
9.1 CTLA-4-Inhibitors Pipeline Overview
9.2 PD-1-Protein-Inhibitors Pipeline Overview
9.3 PD-1-Protein-Inhibitors Pipeline Overview

Global Immune Checkpoint Inhibitors Market Dynamics
10.1 Favorable Parameters
10.2 Challenges to Market Growth

Future Potential of Immune Checkpoint Inhibitors
11.1 Current Therapeutic Eminence
11.2 Upcoming Market Opportunities

PDL1-Protein-Inhibitors Clinical Pipeline by Company, Indication and Phase
12.1 Research
12.2 Preclinical
12.3 Clinical
12.4 Phase-I
12.5 Phase-I/II
12.6 Preregistration

Marketed PDL1-Protein-Inhibitors Clinical Insight by Company and Phase
13.1 Pembrolizumab (Keytruda)
13.2 Atezolizumab (TECENTRIQ)

CTLA-4-Inhibitors Clinical Pipeline by Company, Indication and Phase
14.1 Research
14.2 Preclinical
14.3 Phase-I
14.4 Phase-III

Marketed CTLA-4-Inhibitors Clinical Insight by Company, Phase and Indication
15.1 Ipilimumab (Yervoy)

PD-1-Protein-Inhibitors Clinical Pipeline by Company, Phase and Indication
16.1 Research
16.2 Preclinical
16.3 Phase-I
16.4 Phase-I/II
16.5 Phase-II
16.6 Phase-II/III

Marketed PD-1-Protein-Inhibitors Clinical Insight by Company and Phase
17.1 Pembrolizumab (Keytruda)

Competitive Landscape
18.1 Advaxis
18.2 Agenus
18.3 Amgen
18.4 Bristol Myers Squibb
18.5 Faron Pharmaceuticals
18.6 Genentech
18.7 Genocea
18.8 Incyte Corporation
18.9 Innate Pharma
18.10 Kite Pharma
18.11 MacroGenics
18.12 Merck
18.13 NewLink Genetics Corp
18.14 Sorrento Therapeutics
18.15 TG Therapeutics

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Immune Check Point Inhibitors Clinical Pipeline Has 79 Drugs In Pipeline here

News-ID: 615037 • Views: 1044

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases


More Releases for Inhibitors

Global Protein Kinase Inhibitors Market Research Report
This report studies the global Protein Kinase Inhibitors market status and forecast, categorizes the global Protein Kinase Inhibitors market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Bayer Astra Zeneca Roche Teva Apotex Novartis Glaxosmithkline Pfizer Geographically, this report studies the top
PARP Inhibitors Market Trends and Segments
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These
Tyrosine Kinase Inhibitors - Pipeline Insights 2017
The “Tyrosine kinase Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of tyrosine kinase inhibitor drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Akt inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
AKT Inhibitors - Pipeline Insights 2017
The “AKT Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of AKT drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential AKT inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and
AKT Inhibitors - Pipeline Insights 2017
The “AKT Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of AKT drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential AKT inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and
CDK Inhibitors Therapeutics Pipeline Analysis 2017
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation. Explore Report at: www.psmarketresearch.com/market-analysis/cdk-inhibitors-therapeutics-pipeline-analysis USFDA granted Breakthrough Therapy Designation to a drug